Clinical trials and drug development for neurodegenerative disorders have often failed because of the complex pathophysiological changes occurring during the disease process; therefore, more in vivo experimental evidence is needed to determine whether CCT2 can be a potential therapeutic target against neurodegenerative diseases. Here, CCT2 is linked to neurodegenerative disease.